Home Inherited Disease and Carrier Screening Polycystic Kidney Disease Genetic Test: PKD1, PKD2 Genes, and Results

Polycystic Kidney Disease Genetic Test: PKD1, PKD2 Genes, and Results

By
Vita Library
-
5
Learn how PKD1 and PKD2 genetic testing confirms ADPKD, explains inheritance, clarifies uncertain results, and guides family testing and kidney follow-up.

A polycystic kidney disease genetic test looks for inherited changes that explain cyst formation, most often in PKD1 or PKD2. It can confirm autosomal dominant polycystic kidney disease (ADPKD), clarify an uncertain imaging diagnosis, identify the familial variant for relatives, and support reproductive planning. Genetic testing is especially useful when a person is young, has few cysts, has no clear family history, is being evaluated as a living kidney donor, or has an atypical pattern that could reflect another cystic kidney disorder.

The result does not replace kidney imaging, blood pressure measurement, kidney-function testing, or specialist care. A pathogenic PKD1 or PKD2 variant can establish the molecular diagnosis, but it cannot state the exact age when kidney failure will occur. A negative result also does not always rule out inherited disease because some variants are technically difficult to detect or may lie in another gene. The most useful interpretation combines the laboratory report with age, family history, cyst distribution, total kidney volume, and clinical findings.

  • PKD1 and PKD2 cause most typical ADPKD, but broader panels may be needed for unusual presentations.
  • A positive pathogenic or likely pathogenic result usually confirms a dominant inherited disorder.
  • Each child of an affected person generally has a 50% chance of inheriting the familial variant.
  • PKD1 is technically challenging because nearby pseudogenes closely resemble part of the gene.
  • A negative result is most informative when the laboratory has strong PKD1 coverage and deletion/duplication analysis.
  • Results should be reviewed with nephrology and genetics professionals before testing relatives or making reproductive decisions.

Table of Contents

What the test evaluates

The test evaluates DNA for variants associated with inherited polycystic kidney disease. For a person with a classic ADPKD pattern, the main genes are PKD1 and PKD2. PKD1 encodes polycystin-1, and PKD2 encodes polycystin-2. These proteins work together in kidney tubular cells and other tissues. A disease-causing change can disrupt cell signaling and contribute to progressive cyst formation and kidney enlargement.

ADPKD is more than a collection of kidney cysts. It can involve high blood pressure, blood in the urine, kidney stones, cyst infection, chronic pain, liver cysts, and gradual loss of kidney function. Some people also have clinically important blood-vessel, heart-valve, or abdominal-wall complications. The condition varies widely, even within one family.

A single-gene or focused two-gene test may be appropriate when the family’s clinical diagnosis is secure. Many laboratories instead use a multigene panel because several other genes can produce overlapping kidney or liver cyst patterns. Depending on the laboratory, a panel may include GANAB, DNAJB11, ALG5, ALG8, ALG9, IFT140, HNF1B, PKHD1, and other genes. These alternatives matter because they may have different inheritance patterns, organ involvement, and expected kidney course.

The test usually looks for small sequence variants and larger deletions or duplications. Some laboratories also assess selected deep intronic or regulatory regions, but coverage differs. The report should specify the genes, transcript versions, regions analyzed, assay limitations, and whether deletion/duplication testing was included.

The title “polycystic kidney disease test” can be misleading because not every cystic kidney condition is inherited in the same way. PKD1 and PKD2 are associated mainly with autosomal dominant disease. Autosomal recessive polycystic kidney disease is usually related to biallelic PKHD1 variants and often begins in infancy or childhood. Acquired cystic kidney disease, simple cysts, and cysts associated with aging are not diagnosed by finding a PKD1 or PKD2 variant.

Who may benefit from testing

Genetic testing is not required for every person with a typical family history and age-specific imaging findings. Ultrasound, CT, or MRI may establish ADPKD in many adults. Testing becomes particularly valuable when imaging alone cannot answer the question or when a molecular result will change decisions.

Common reasons include:

  • A young adult at 50% familial risk whose ultrasound is normal or equivocal
  • Kidney cysts without a known family history
  • Very early, unusually severe, or childhood-onset disease
  • Atypical imaging, such as one-sided, asymmetric, small-kidney, or predominantly liver-cyst disease
  • Evaluation of a biologically related potential living kidney donor
  • A family in which several cystic kidney diagnoses are possible
  • Planning prenatal testing or preimplantation genetic testing
  • Confirming the familial variant so relatives can receive targeted testing

Testing can also help distinguish ADPKD from a phenocopy, meaning a different disorder that looks similar. This is important when kidney size, cyst distribution, diabetes, electrolyte abnormalities, congenital anomalies, liver findings, or family history do not fit typical PKD1- or PKD2-related disease.

A person with no affected relatives can still have ADPKD. The variant may have arisen for the first time in that person, a parent may have mild or unrecognized disease, the family may be small, or medical information may be unavailable. Mosaicism is another possibility: a variant may be present in only a proportion of a parent’s cells, producing mild findings and a lower but not zero transmission risk.

Testing an affected family member first is usually the most efficient strategy. Once a clearly disease-causing variant is identified, unaffected or uncertain relatives can have targeted analysis for that exact change. Testing an unaffected relative with no known familial variant is harder to interpret because a negative result may reflect assay limits or the wrong gene rather than absence of inherited risk.

Before testing, patients should consider possible effects on anxiety, family relationships, reproductive choices, and insurance or employment protections, which vary by location and policy type. Children at risk require special discussion because ADPKD can have treatable childhood manifestations, particularly high blood pressure, but predictive testing also raises autonomy and psychosocial concerns. The decision should reflect the child’s clinical needs and the family’s values rather than a fixed rule.

How testing is performed

Most tests use blood or saliva. The laboratory extracts DNA and analyzes PKD1, PKD2, or a larger cystic kidney disease panel. The basic sequence is straightforward for the patient, but the technical work behind PKD1 analysis is unusually demanding.

The duplicated portion of PKD1 has six nearby pseudogenes that are highly similar to the true gene. A method that does not reliably separate PKD1 from these look-alike sequences can miss variants or assign a change to the wrong location. High-quality laboratories may use validated short-read sequencing with specialized bioinformatics, long-range polymerase chain reaction, Sanger confirmation, genome sequencing, or long-read approaches. The report or test description should clearly state that the method is designed for PKD1’s duplicated region.

A complete molecular evaluation commonly includes:

  1. Sequence analysis: detects many single-nucleotide changes and small insertions or deletions.
  2. Deletion/duplication analysis: detects missing or extra exons or larger gene segments.
  3. Broader panel testing: considers other cystic kidney genes when the phenotype is atypical or initial testing is negative.
  4. Targeted familial testing: checks only the known variant in relatives once the family change is established.
  5. Additional studies: RNA analysis, genome sequencing, or long-read sequencing may clarify suspected splice variants or technically unresolved regions.

The ordering clinician should provide a detailed phenotype and pedigree. Age at diagnosis, kidney imaging pattern, total kidney volume if measured, liver cysts, kidney function, hypertension, aneurysm history, diabetes, hearing or eye findings, and relatives’ diagnoses can guide variant interpretation. A laboratory interpreting DNA without this context may be less able to distinguish the best explanation from an incidental finding.

Turnaround time varies from a few weeks to several months, especially when confirmatory or family studies are needed. A report should identify the reference transcript, exact DNA and protein notation, classification, evidence summary, inheritance pattern, and test limitations. For broader education about methods and result categories, a genetic testing overview can help patients prepare for the laboratory language.

Understanding positive, negative, and uncertain results

A result should be interpreted by classification and by whether it fits the person’s clinical picture.

Pathogenic or likely pathogenic result

One pathogenic or likely pathogenic variant in PKD1 or PKD2 usually confirms ADPKD in a person with compatible findings. “Likely pathogenic” is a formal laboratory category indicating strong evidence for disease causation; it is not merely a guess. The report may also describe the variant as truncating, nontruncating, splice-altering, deletion, duplication, or mosaic.

A positive result can support diagnosis, family testing, donor evaluation, and reproductive planning. It does not mean every possible complication will occur. It also does not automatically determine whether a person is currently a rapid progressor or qualifies for a specific treatment.

Negative result

A negative result means the laboratory did not identify a reportable disease-causing variant with the method used. Its meaning depends heavily on the starting situation.

If a relative has a known familial PKD1 or PKD2 variant and the tested person is negative for that exact variant, the result is usually highly reassuring for that familial disorder. If no family variant is known, a negative panel is less definitive. Possible explanations include a variant outside the analyzed regions, a complex structural change, low-level mosaicism, a gene not included on the panel, an undetected splice effect, or a non-genetic cause of the cysts.

The laboratory’s PKD1 method matters. A negative test with incomplete coverage of duplicated exons is not equivalent to a negative test from a fully validated assay. Clinicians should review the technical limitations rather than relying on the word “negative” alone.

Variant of uncertain significance

A variant of uncertain significance, or VUS, is a DNA change for which current evidence is insufficient to call it disease-causing or benign. A VUS should not be used by itself to diagnose ADPKD, exclude a kidney donor, test a pregnancy, or make irreversible treatment decisions. Family segregation, improved population data, functional evidence, RNA studies, or later reclassification may resolve it.

A VUS that tracks with disease in several relatives may become more suspicious, but the laboratory or genetics team should perform the formal evaluation. Patients should not ask healthy relatives to undergo casual “VUS testing” without a plan for how the result will be interpreted. The principles in a VUS result guide apply directly here.

Benign or likely benign finding

Benign and likely benign variants are not considered the cause of the condition and generally should not guide care. Reports may omit them or list them separately.

Two or more reportable findings

Occasionally a person has more than one relevant variant, such as a PKD1 variant plus a second cystic kidney gene finding. The combined effect may contribute to unusually early or severe disease, but interpretation requires specialist review and often testing of parents or other relatives to determine whether variants are on the same or different chromosome copies.

Inheritance and family testing

PKD1- and PKD2-related ADPKD follow an autosomal dominant pattern. A person with one pathogenic variant generally has a 50% chance of passing that variant to each child. The probability resets with every pregnancy; having one affected or unaffected child does not change the next child’s chance.

Men and women can inherit and transmit the variant. Severity is not reliably copied from parent to child. A child may have a milder, similar, or more severe course than the affected parent because the specific variant, additional genetic factors, blood pressure, lifestyle, and chance all influence expression.

When a familial variant is known, targeted testing is usually the cleanest option for adult relatives. A relative who tests positive should receive baseline clinical assessment, including blood pressure, kidney function, urine evaluation, and appropriate imaging. A relative who tests negative for the proven familial variant usually does not need ADPKD surveillance based on that family history, although unrelated kidney findings still deserve ordinary medical evaluation.

A new, or de novo, variant can occur. If neither parent has the variant in a standard blood sample, recurrence risk for siblings is usually low but not zero because a parent may have germline or low-level mosaicism. The affected individual still has up to a 50% chance of transmitting the variant to each child.

Reproductive options may include natural conception with or without prenatal diagnosis, in vitro fertilization with preimplantation genetic testing for a monogenic condition, donor eggs or sperm, adoption, or choosing not to have children. Prenatal and embryo testing generally require a clearly established familial pathogenic variant; a VUS is usually not an appropriate target. A genetics professional can explain test accuracy, timing, limitations, and the fact that a positive fetal result does not predict exact adult severity. General information about prenatal genetic testing can support that discussion.

Living kidney donation creates a particularly high-stakes family-testing situation. A related potential donor must be evaluated for their own safety. When the recipient’s familial variant is known, targeted testing can often clarify risk. When it is not known, donor assessment may require age-appropriate imaging, comprehensive genetic testing, and review by a transplant team experienced in inherited kidney disease. A negative result from a weak or incomplete assay should not be treated as proof that donation is safe.

What genotype can and cannot predict

Genotype provides useful population-level information, but it is not a personal countdown clock.

On average, truncating PKD1 variants are associated with more rapidly progressive kidney disease than many nontruncating PKD1 variants, and PKD2-related disease often progresses later than PKD1-related disease. Some nontruncating or incompletely penetrant variants have milder effects. However, there is substantial overlap. People with the same family variant can reach kidney failure decades apart, and some never reach it during their lifetime.

Clinical prognosis therefore combines several forms of evidence:

  • Age and estimated glomerular filtration rate (eGFR)
  • Change in eGFR over time
  • Kidney size and cyst distribution
  • Height-adjusted total kidney volume and Mayo Imaging Classification when appropriate
  • Early hypertension or urologic events
  • Sex and family history of kidney failure
  • Genotype, including whether a PKD1 variant is truncating

The PROPKD score is one tool that incorporates genotype with clinical features, but it applies only in defined circumstances and is not a substitute for specialist judgment. The Mayo Imaging Classification is useful for typical bilateral diffuse disease, not every atypical cyst pattern. A result in a rarer gene may not fit prediction systems developed for PKD1 and PKD2.

Genetic testing also does not decide by itself whether to use tolvaptan. That treatment is considered for selected adults at risk of rapid progression and requires discussion of benefits, frequent urination and thirst, liver monitoring, medication interactions, pregnancy considerations, and personal preferences. The molecular result may contribute to risk assessment, but serial kidney function and imaging often carry more immediate prognostic weight.

Likewise, a PKD1 or PKD2 result does not automatically determine who needs intracranial aneurysm screening. Decisions consider personal history, family history of aneurysm or subarachnoid hemorrhage, high-risk occupation, upcoming major surgery or transplantation, symptoms, and informed preference. Sudden severe “worst headache,” neurologic deficit, collapse, or new seizure is an emergency regardless of genotype.

Follow-up after results

A positive molecular diagnosis should lead to a coordinated care plan rather than repeated DNA testing. Nephrology follow-up usually focuses on blood pressure, kidney function, urine findings, kidney size when clinically useful, cardiovascular risk, pain, stones, infection, and preparation for kidney replacement therapy if disease becomes advanced.

Blood pressure can rise before kidney function declines. Home measurements may reveal hypertension that is missed in a single clinic reading. Treatment plans often include sodium reduction, physical activity, weight management, smoking avoidance, and medication when indicated. Hydration advice should be individualized, especially for people with heart disease, advanced kidney disease, or medicines that alter water balance.

Patients should learn which symptoms require prompt attention. Fever with flank pain may indicate a cyst infection; visible blood in urine may follow a cyst bleed or stone but still needs assessment; persistent pain may require imaging and a structured pain plan. Severe headache, focal weakness, speech difficulty, or loss of consciousness requires emergency evaluation.

A positive result can also prompt discussion of liver cyst burden, pregnancy, contraception, and medication safety. Pregnancy is often successful, but hypertension and reduced kidney function can increase maternal and fetal risk. Preconception review should include kidney function, blood pressure control, and whether current medications are safe in pregnancy.

The report itself should be retained permanently. Keep the laboratory name, accession number, gene, transcript, exact variant, classification, and testing method. Reclassification can occur, especially for VUS findings. Patients should ask who is responsible for future updates and how to contact the laboratory after moving or changing clinicians.

A negative or uncertain result may justify broader testing, review of raw data, updated imaging, testing another affected relative, or reanalysis after new genes and methods become available. In a person with compelling clinical ADPKD, management should continue according to the clinical diagnosis even if molecular testing remains unresolved. A genetic diagnostic result guide can help organize questions for the follow-up visit.

Practical questions and test limitations

Before ordering, ask the laboratory or clinician several concrete questions:

  • Does the assay fully cover the duplicated region of PKD1?
  • Are exon-level and larger deletions or duplications assessed?
  • Which alternative cystic kidney genes are included?
  • Can the test detect low-level mosaicism, and at what approximate level?
  • Will suspected splice variants be evaluated with RNA or other follow-up studies?
  • Are parental or family studies available when interpretation is uncertain?
  • How are result updates communicated?

Technical limitations are not the only source of uncertainty. A variant can be real yet have reduced penetrance, meaning not everyone who inherits it develops the same degree of disease. Some variants affect mainly liver cysts; some rare genes produce smaller kidneys or a slower decline; and some individuals have more than one genetic contributor. Clinical context is essential.

Sample history can also matter. A blood sample from someone who has received an allogeneic bone marrow or stem-cell transplant may reflect donor DNA rather than the patient’s inherited DNA. In that situation, a laboratory may request cultured skin cells or another non-blood source. Kidney transplantation does not replace the person’s inherited DNA in blood, but transplant status and immunosuppression remain important for clinical management.

Direct-to-consumer raw data are not adequate to confirm or exclude ADPKD. Consumer arrays test selected positions and may not reliably analyze PKD1’s complex regions. Any potentially important finding should be confirmed in a clinical laboratory before it affects care or family testing.

The best report is one that answers the question that led to testing. For a person with classic disease, that may be confirmation and a familial marker. For a donor candidate, it may be reliable exclusion of a known variant. For an atypical case, it may require a broader panel or genome-level method. For a family planning pregnancy, it must identify a clear pathogenic variant suitable for targeted testing. Choosing the right assay is as important as interpreting the result.

Genetic information should be integrated with imaging rather than set against it. Imaging shows current anatomy and cyst burden; DNA identifies the inherited cause and family risk. Kidney-function testing shows present physiologic impact; longitudinal data show direction of change. Together, these tools provide a more accurate and useful picture than any one result alone.

References

Disclaimer

This article provides general education about inherited polycystic kidney disease testing and is not a diagnosis or individual treatment plan. Imaging, kidney function, blood pressure, family history, and the laboratory’s PKD1 methods must be reviewed with qualified nephrology and genetics professionals. Seek urgent care for sudden severe headache, new neurologic symptoms, severe flank pain with fever, inability to urinate, or other acute concerns.

RELATED ARTICLESMORE FROM AUTHOR